SCHEMBL5538441

SCHEMBL5538441

O=C(NCCCN1CCCC1=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(Cc2cccnc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
TSHR P16473 3/20 0.49
TYRO3 Q06418 1/20 0.44
RXFP1 Q9HBX9 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 6/20 0.41
GAA P10253 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 3/20 0.40
HTT P42858 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
TLR2 O60603 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539009 0.92 ALDH1A1 (0.43) ALDH1A1TSHRTYRO3RXFP1CYP2C19
SCHEMBL5547092 0.89 CYP2C19 (0.46) ALDH1A1TSHRRXFP1CYP2C19KDM4E
SCHEMBL5539930 0.89 CYP2C19 (0.46) ALDH1A1TSHRRXFP1CYP2C19KDM4E
SCHEMBL5546009 0.89 CYP2C19 (0.46) ALDH1A1TSHRRXFP1CYP2C19KDM4E
SCHEMBL5545520 0.88 KDM4E (0.43) ALDH1A1TSHRRXFP1CYP2C19KDM4E
SCHEMBL5539125 0.88 CYP2C19 (0.45) ALDH1A1TSHRRXFP1CYP2C19KDM4E
SCHEMBL5540840 0.87 ALDH1A1 (0.49) ALDH1A1TSHRTYRO3RXFP1CYP2C19
SCHEMBL5541025 0.87 CYP2C19 (0.45) ALDH1A1TSHRRXFP1CYP2C19KDM4E
SCHEMBL5543248 0.87 CYP2C19 (0.45) ALDH1A1TSHRRXFP1CYP2C19KDM4E
SCHEMBL15163636 0.87 ALDH1A1 (0.43) ALDH1A1TSHRRXFP1CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885TSHR 4052/4885TYRO3 3506/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885TSHR 4622/4885TYRO3 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.